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Abstract
Neuroblastoma is an embryonal malignancy that originates in the sympathetic nervous 
system. It is the most common solid tumor in infants and the most frequent extracranial 
solid tumor in children. Neuroblastoma accounts for 10% of childhood malignancies with 
75% occurring in children <4 years. Stage, age, clinical and tumor genomic features are 
the principal criteria for determining treatment policy. Treatment modalities traditionally 
employed in the management of neuroblastoma are surgery, chemotherapy, and radio-
therapy. Intensive multimodal treatment in patients with neuroblastoma has resulted in 
improved survival rates. However, there is a considerable percentage of patients with 
refractory and relapsed disease. Targeted therapy for neuroblastoma involves treatment 
aimed at molecular targets that have a unique expression in this childhood cancer. A 
large number of molecular targets have been identified for the treatment of high-risk and 
relapsed neuroblastoma. Treatment in this way aims at providing a more selective way 
to treat the disease and decreasing toxicities associated with the conventional treatment 
regimen.
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1. Introduction
Neuroblastoma, originating in neural crest cells, can occur anywhere along the sympathetic 
nerve chain. By far the most common location for a primary tumor is the adrenal gland. 
In its most primitive form, the histology of neuroblastoma is marked by poorly differenti-
ated small, round blue cells. At an intermediate stage of maturation, there is differentiation 
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toward ganglion cells. Tumors composed of a mixture of neuroblasts and mature ganglion 
cells are classified as ganglioneuroblastomas. At the most differentiated end of the spectrum 
is ganglioneuroma, a benign tumor composed entirely of mature ganglion cells, neuritis, and 
Schwann cell [1].
At diagnosis, 65% of patients have disseminated disease, most commonly spreading to the bone. 
Disseminated disease is typically manifested as fever and bone pain. Additionally, neuroblas-
toma is associated with a paraneoplastic syndrome of opsoclonus-myoclonus (“dancing eyes and 
feet syndrome”) [2].
Treatment modalities traditionally employed in the management of neuroblastoma are sur-
gery, chemotherapy, and radiotherapy. Recently immunotherapy has been established as an 
important component of advanced neuroblastoma treatment. Intensive multimodal treatment 
strategies improved the survival in children with neuroblastoma. However, issues related to 
treatment refractoriness and late effects as well as disease recurrence remain significant chal-
lenges [3].
Multiple therapeutic targets have been developed to offer an advantage of treating neuro-
blastoma in a more selective way to maximize the treatment efficacy and minimize its 
toxicity [3].
1.1. Neuroblastoma staging systems
Several staging systems have been used to classify disease extent. The International Neuroblastoma 
Staging System (INSS), which is based on clinical and surgical evaluations, was developed by 
consensus of major pediatric oncology groups (POGs) in the United States, Europe, and Japan. 
The INSS differentiates between INSS stages 1, 2A, 2B, 3, 4, and 4S, based on surgical excision, 
lymph node involvement, and metastatic sites [4].
Because the INSS is a surgically based staging system, the stage for patients with locoregional 
disease can vary based on degree of surgical resection. Noteworthy, patients with localized 
disease who will not undergo surgery cannot be adequately staged. For these reasons, the 
International Neuroblastoma Risk Group (INRG) Task Force developed a new pretreat-
ment staging system in 2005 based on clinical criteria and specific image-defined risk fac-
tors. Required imaging modalities include CT or MRI, as well as MIBG scintigraphy. The 
International Neuroblastoma Risk Group Staging System (INRGSS) differentiates between 
L1, L2, M, and MS stages. The INRGSS differs from the INSS in that the INRGSS is based on 
preoperative imaging characteristics and not on surgical resection. The age for the INRGSS 
MS stage is set at 547 days (18 months) compared with 12 months in the INSS 4S stage 
(Table 1) [5].
1.2. Risk factors and risk stratification
Children’s Oncology Group Neuroblastoma Risk Stratification is the most commonly used tool 
to stratify patients based mainly on tumor stage, patient’s age, MYCN amplification, DNA 
index, and tumor histology (Table 2) [6].
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1.3. Multimodal treatment approach for neuroblastoma
1.3.1. Low-risk disease
Low-risk NB patients require minimal therapy; previous pediatric oncology group (POG) and 
children cancer group (CCG) studies have shown that treatment with surgery alone results in 
survival rate >95% for patients with stage 1 disease. Even if there is microscopic residual  disease, 
adjuvant treatment with radiotherapy or chemotherapy is not indicated [7, 8]. Diploidy and 
unfavorable histology predict for local recurrence and, therefore, careful follow-up is necessary, 
as local recurrence or distant metastasis may rarely occur and require salvage treatment [9].
The primary goals of surgery are to determine an accurate diagnosis, provide accurate  surgical 
staging, completely remove the tumor, offer adjuvant therapy for delayed primary surgery, 
and remove residual disease with second-look surgery [10].
Management of infrequent patient with stage 1 or 2 with NMYC amplification remains con-
troversial. Although patient with MYCN-amplified stage 1 tumor has significantly event-free 
INSS INRGSS
Stage 1: localized tumor with complete gross excision; ± 
microscopic residual disease; representative ipsilateral 
lymph node negative for tumor microscopically
Stage L1: localized tumor not involving vital structures 
as defined by IDRFs and confined to one body 
compartment
Stage 2A: localized tumor with incomplete gross excision; 
ipsilateral lymph node should be negative for tumor 
microscopically
Stage L2: locoregional tumor with the presence of one 
or more IDRFs
Stage 2B: localized tumor with or without complete gross 
excision; ipsilateral lymph node should be positive for 
tumor microscopically, while contralateral lymph nodes 
should be negative microscopically
Equals stage L2
Stage 3: unresectable unilateral tumor crossing the 
midline, ± involvement of regional lymph node, 
or localized unilateral tumor with involvement of 
contralateral regional lymph node or midline tumor with 
bilateral extension by infiltration (unresectable) or by 
lymph node involvement
Equals stage L2
Stage 4: primary tumor with dissemination to distant 
lymph nodes, bone, bone marrow, liver, skin, or other 
organs
Stage M: distant metastatic disease (except stage MS). 
Distant lymph node involvement is metastatic disease. 
Ascites and pleural effusion, even if malignant cells are 
present, do not constitute metastatic disease unless they 
are remote from the primary tumor
Stage 4S: localized primary tumor in infants younger 
than age 1 year (localized as in stage 1, 2A, or 2B) with 
dissemination limited to the skin, liver, or bone marrow 
(<10% malignant cells)
Stage MS: metastatic disease in children younger than 
547 days (18 months) of age with metastases confined 
to the skin, liver, and/or bone marrow (<10% malignant 
cells); MIBG scan must be negative in the bone and 
bone marrow. Primary tumor can be L1 or L2 with no 
limitations in terms of crossing or infiltration of the midline
Table 1. Comparison between INSS and INRGSS.
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survival rate [11], a subset may achieve long-term remission following surgery alone. These 
rare cases may require continued prospective evaluation to clarify optimal management [12].
1.3.1.1. Stage 4S disease
Infants with stage 4S disease have, in general, a good prognosis; high survival rate has been 
reported in those infants whose tumor lacks MYCN amplifications [13]. Interestingly Tonini 
and colleagues reported that, in Italian experience, favorable outcomes were also seen in infants 
with MYCN-amplified stage 4S neuroblastoma [14]. The tumor may regress  spontaneously 
due to programmed cell death and, therefore treatment is not always necessary. If there are no 
distressing or life-threatening symptoms, it is possible to follow an observation policy hoping 
Stage Age MYCN Ploidy Histology Other Risk group
1 Low
2A/2B Not amplified >50% resection Low
Not amplified <50% resection Intermediate
Not amplified Biopsy only Intermediate
Amplified High
3 <547 days Not amplified Intermediate
≥547 days Not amplified Favorable Intermediate
Amplified High
≥547 days Not amplified Unfavorable High
4 <365 days Amplified High
<365 days Not amplified Intermediate
365–547 days Amplified High
365–547 days DI = 1 High
365–547 days Unfavorable High
365–547 days Not amplified DI > 1 Favorable Intermediate
≥547 days High
4S <365 days Not amplified DI > 1 Favorable Asymptomatic Low
<365 days Not amplified DI = 1 Intermediate
<365 days Missing Missing Missing Intermediate
<365 days Not amplified Symptomatic Intermediate
<365 days Not amplified Unfavorable Intermediate
<365 days Amplified High
Table 2. Children’s Oncology Group neuroblastoma risk stratification schema.
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for spontaneous regression. Nonintensive chemotherapy is called for if there are major symp-
toms, e.g., massive hepatomegaly causing respiratory distress. Alternatively, low-dose irradia-
tion may precipitate regression [15].
1.3.1.2. More advanced operable disease
Patients with lymph node involvement, that is, stage 2B and some stage 3 cases, are treated 
principally by surgery. The need for adjuvant treatment depends on age. In infants <6 months, 
the role of chemotherapy is controversial. However, in older children, chemotherapy is defi-
nitely warranted, using a schedule such as “OPEC,” which comprises vincristine, cisplatin, 
etoposide, and cyclophosphamide [16]. It is often preferable to use chemotherapy as the initial 
treatment in these patients aiming at reducing the tumor bulk, making complete removal 
more likely and the surgery safer. Data from POG in patients with stage 2B and stage 3 dis-
ease have shown that complete resection is not associated with a significantly better event-
free survival than incomplete resection, while patients with favorable Shimada histology have 
a significantly better event-free survival rate at 2 years than those with unfavorable Shimada 
(92% versus 58%, respectively) [17].
Irradiation of the tumor bed to eradicate residual disease is controversial.
In a retrospective review of patients with Children’s Cancer Study Group (CCSG) stage II 
disease, no significant benefit was observed in irradiated children [18]. POG designed a ran-
domized trial to evaluate the role of placing radiotherapy in addition to chemotherapy in 
patients >1 year with nodal disease detected at resection of the primary tumor. Significantly 
improved local control and survival rates were seen in irradiated children [19]. As the che-
motherapy protocol used in this study was less intensive than that now considered standard, 
it remains possible that more intensive chemotherapy might be as good as combined chemo-
therapy and radiotherapy in the POG trial. Based on the fact that patients with biologically 
favorable tumors have a good prognosis [20], even in the presence of residual disease, it is 
reasonable not to irradiate patients with biologically favorable stage 2B and stage 3 tumors, 
with or without residual disease after chemotherapy and surgery. Despite the adverse effects 
of radiotherapy in young children, it should be considered in the treatment plan of patients 
with biologically unfavorable stage 2B and stage 3 tumors with residual disease [21].
1.3.2. Intermediate-risk disease
Intermediate-risk patients with favorable biology tumors are treated with a short course 
of chemotherapy (four cycles), while intermediate-risk patients with unfavorable biology 
receive a longer course of chemotherapy (eight cycles).
In previous POG studies, treatment for infants with regional and metastatic disease was strat-
ified by tumor cell ploidy and MYCN amplification status. Infants with hyperdiploid tumors 
were treated with cyclophosphamide and doxorubicin, whereas infants with diploid tumors 
were treated with cisplatin and teniposide after an initial course of cyclophosphamide and 
doxorubicin [22].
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1.3.3. High-risk disease
Survival for high-risk neuroblastoma patients has improved modestly during the past 20 
years, although cure rates remain low [23]. This improvement was attributed to  intensification 
of induction chemotherapy, megatherapy consolidation, as well as improved supportive care. 
Chemotherapy dose intensity has been reported to correlate strongly with both response and 
progression-free survival where response rates 70–80% have been observed with intensive 
multiagent induction treatment protocols [24]. Intensification of consolidation therapy with 
autologous hematopoietic stem cell transplantation following myeloablative conditioning 
chemotherapy with or without total body irradiation also contributes to improved overall 
survival in several single-armed studies [25].
Patients with advanced neuroblastoma such as those with stage 4 or inoperable stage 3 disease 
should receive initial chemotherapy with “OPEC” or a similar protocol. In stage 3 patients, 
if chemotherapy rendered the tumor operable, it should be removed. In stage 4 patients, 
surgery to remove residual primary tumor should also be considered complete remission at 
all metastatic sites has been achieved. Dose intensification treatment strategies, designed to 
achieve a greater degree of cytoreduction and to circumvent emergence of resistant clones by 
using a larger number of non-cross-resistant chemotherapeutics in higher doses over a shorter 
time, are feasible but have not yet proved significantly superior to OPEC [26].
1.3.3.1. Megatherapy
Megatherapy combining high-dose myeloablative chemotherapy and/or total-body irra-
diation with either autologous bone marrow transplantation or peripheral blood stem 
cell reinfusion is often used in advanced neuroblastoma. The rationale of megatherapy 
is to eradicate the undetectable minimal residual disease and prevent disease relapse. 
Chemotherapeutics at higher-dose levels can bypass inadequate membrane transport and 
saturate detoxification pathways and DNA repair mechanisms and therefore attack resid-
ual tumor cells which have survived initial chemotherapy and became resistant to chemo-
therapy at conventional doses. Single-agent high-dose melphalan, which was evaluated in 
European Neuroblastoma Study Group (ENSG) trial 1, is one of the more commonly used 
conditioning regimens [27].
Radiation, usually in the form of TBI, has been evaluated with high-dose chemotherapy and 
autologous bone marrow transplantation in treatment of advanced neuroblastoma, and the 
results were not superior to those achieved by chemotherapy alone, yet the early and late side 
effects were greater. Allogeneic BMT is not associated with improved results. The European 
Blood and Marrow Transplant Group has reviewed the data of more than a thousand of neu-
roblastoma patients who have received myeloablative therapy. Overall, survival was 33% at 
5 years, but relapses may still be seen later. When patients relapsed after initial autologous 
BMT, salvage was not possible, but autologous BMT did salvage 15% of patients in the second 
or subsequent relapse who had not previously undergone transplantation. The poor outcome 
for transplantation in stage 4 patients > 1 year is mainly due to persistent skeletal or bone 
marrow involvement [28].
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2. Promising therapeutic targets of neuroblastoma
The 5-year event-free survival for high-risk neuroblastoma is <50%, including children 
with metastatic neuroblastoma >18 months of age and patients with locoregional or meta-
static  neuroblastoma with MYCN amplification [5]. Improved outcome was achieved with 
intensive combination induction chemotherapy and surgery, followed by myeloablative 
therapy with hematopoietic stem cell transplantation and then differentiation therapy with 
isotretinoin. Isotretinoin is the first tumor-targeted therapy with established activity in 
neuroblastoma [29]. After that, a large number of molecular targets have been developed 
for treatment of high-risk, refractory, and relapsed neuroblastoma. These molecular tar-
gets can supplement or replace some of the intensive chemotherapy used for treatment of 
neuroblastoma.
2.1. Potential advantages of target therapy over conventional chemotherapy
1. Effective cancer treatment with less side effects (increased therapeutic index) due to the 
targeting of a unique characteristic within the tumor cells, which is usually absent in nor-
mal body cells
2. Decreased likelihood of the development of resistance to the targeted therapy due to the 
molecular target being essential for the viability of the cancer
2.2. Targeting human norepinephrine transporter (hNET) with 
131I-metaiodobenzylguanidine (MIBG)
The rationale for using 131 I-MIBG as a targeted radiopharmaceutical for high-risk neuroblas-
toma was based on the observation that 90% of these tumors are MIBG avid. Studies reported 
impressive response rates in relapsed disease, and in the largest phase II trial, 37% of patients 
had a partial response (PR) or complete response (CR) [30].
Many efforts were made to maximize the benefits of MIBG:
a. Increasing tumor radiation dose: the response rate of 42 mCi/kg dose did not appear to be 
different from that obtained with the standard 18 mCi/kg dose [31].
b. Repeated MIBG infusions: investigators reported a benefit from repeated MIBG infusions 
given 6–12 weeks apart, with continued improved response in some of the patients with 
each successive infusion [32].
c. Different isotope (125 I-MIBG): the results were disappointing [33].
d. No carrier added: this approach had the advantage of infusion over 30 min instead of 
90–120 min. However, NANT trial showed toxicity, and efficacy profiles equal to those 
observed with the standard preparation [34].
e. MIBG combined with radiosensitizers or chemotherapy:
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• Italian investigators treated 16 children with refractory or relapsed neuroblastoma using 
131I-MIBG combined with cisplatin and cyclophosphamide with or without etoposide and 
vincristine and obtained 12 PRs [35].
• Two studies investigated MIBG combined with a camptothecin, with tolerable toxicity and 
measurable response [36, 37].
• Combination of a histone deacetylase inhibitor (Vorinostat) with 131I-MIBG showed that 
Vorinostat at 180 mg/m2/dose is tolerable with 18 mCi/kg MIBG, and A phase II trial com-
paring this regimen to single-agent MIBG is ongoing [38].
• 131I-MIBG before standard induction therapy with 66% response rate [39].
• 131I-MIBG at the end of induction and before myeloablative therapy for patients with re-
sidual MIBG-positive disease reported a response rate of 46% but no improvement in over-
all survival [40].
2.3. GD2-targeted immunotherapy of high-risk neuroblastoma
Promising results have been emerged with immunotherapy targeting the surface glycolipid 
molecule disialoganglioside (GD2) that is uniformly expressed by neuroblastomas and gliomas, 
sarcomas, and some melanomas [41].
GD2 expression is weak in normal human tissues and restricted to neurons, melanocytes, and 
peripheral pain fibers. Based on this, GD2 seems to be an ideal antigen target for immuno-
therapy of neuroblastoma [41].
2.3.1. Mechanism of action
a. CDC: complement-dependent cytotoxicity
b. ADCC: antibody-dependent cell cytotoxicity
2.3.1.1. First-generation anti-GD2 mAbs
Many phase I and phase II clinical trials led to the pivotal randomized COG phase III study. 
This study was conducted on 226 eligible patients to determine whether immunotherapy with 
ch14.18 combined with GM-CSF, IL-2, and isotretinoin would improve survival compared to 
isotretinoin alone for children with high-risk neuroblastoma in the first response after mye-
loablative therapy and stem cell rescue. EFS was significantly higher for patients randomized 
to immunotherapy, with a 2-year estimated EFS from randomization of 66% versus 46% for 
patients randomized to isotretinoin alone (P = 0.01). The immunotherapy group also showed 
significantly higher OS (86% versus 75% at 2 years; P = 0.02). This represents the first success-
ful immunotherapy to target a nonprotein antigen [42].
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2.3.1.2. Second-generation anti-GD2 mAbs
Phase II study of Hu14.18-IL-2 immunocytokine showed 5 CRs in 23 neuroblastoma patients 
evaluable only by bone marrow histology and/or MIBG, but no responses for patients with 
measurable disease. Preliminary findings of a phase I clinical trial of hu14.18K322 showed 
reduced neuropathic pain compared to Hu14.18-IL-2 [43].
Yu and colleagues in 2001 carried out a clinical trial of mAb 1A7 as a GD2 vaccine in 31 chil-
dren with high-risk neuroblastoma who achieved the first or subsequent remissions. No sys-
temic toxicities were observed with subcutaneous injections given periodically over 2 years, 
and only local reactions were seen. Sixteen of 21 children who enrolled during the first remis-
sion had no evidence of disease progression at a median of 6 years, whereas only one of ten 
children in the second remission remains progression-free. Yu and colleagues concluded that 
mAb1A7 vaccine is effective at inducing biologically active anti-GD2, has little toxicity, and 
may be useful for controlling minimal residual disease [44].
2.4. ALK as a therapeutic target in neuroblastoma
Anaplastic lymphoma kinase (ALK) is a tyrosine kinase that is mutated or amplified in about 
10% of neuroblastomas and expressed on the surface of most neuroblastoma cells [45].
There are several reasons why inhibition of ALK would be a feasible therapeutic option in 
neuroblastoma:
1. ALK is expressed on the surface of most neuroblastoma tumor cells and is restricted to the 
brain following development [45].
2. A proportion of neuroblastoma cells that overexpress phosphorylated ALK that is neither 
mutated nor amplified respond to ALK depletion by undergoing apoptosis [46].
3. ALK inhibition may provide an effective targeting strategy against MYCN-amplified tu-
mors [47].
Crizotinib was the first drug to be approved by FDA for treatment of ALK-rearranged can-
cers. Preclinical testing showed the sensitivity of neuroblastoma cell lines with ALK ampli-
fication. Crizotinib is being tested in a phase I/II trial for children with neuroblastoma and 
other solid tumors bearing ALK mutations [48].
2.5. The topoisomerase 1 inhibitors
The topoisomerase 1 inhibitors such as topotecan and irinotecan are often used early for treat-
ment of children with relapsed neuroblastoma because of their acceptable efficacy and toxicity 
profiles. Topotecan efficacy is enhanced when it is combined with low-dose cyclophosphamide. 
Irinotecan and temozolomide are a well-tolerated combination, and efficacy is being studied [49].
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2.6. Retinoids
A randomized clinical trial of 13-cis-retinoic acid following myeloablative chemotherapy 
regimen established the importance of retinoids in therapy for high-risk neuroblastoma. 
Fenretinide produced multi-log cell kill in multiple neuroblastoma cell lines, even those 
resistant to other retinoids [50]. Phase I studies have shown that fenretinide is generally well 
tolerated, and COG phase II trial has been completed. Newer formulations of this drug are 
currently in the pipelines to facilitate oral administration to young children [51].
2.7. Targeting CD133 biomarker
The tumor-initiating properties of CD133 have been discovered through studies such as the 
one performed by Cournoyer et al. Through genotype analysis CD133 expression is found to 
be associated with the expression of the Ephrin-A2 (EFNA2) protein. This protein can play a 
role in cancer development. EFNA2 is expressed in stem cells and can promote the formation 
of tumors. CD133 and the associated EFNA2 protein are in the pipelines as potential thera-
peutic targets for neuroblastoma [52].
2.8. Angiogenesis inhibitors
Tumor vascularity has been correlated with aggressiveness in neuroblastoma. Based on this, 
angiogenesis inhibitors seem to be an attractive therapeutic option. Furthermore, pro-angiogenic 
molecules appear to be differentially expressed in high-risk tumors, whereas lower-risk tumors 
are characterized by a stroma that provides anti-angiogenic molecules in the microenvironment. 
Preclinical studies of anti-angiogenic drugs in neuroblastoma showed promising results [53].
2.9. Targeting insulin-like growth factor I receptor (IGF-IR)
IGF-1R is involved in the regulation of cell proliferation, survival, differentiation, and trans-
formation. IGF-1R is highly expressed in neuroblastoma, and activation of IGF-1R induces 
MYCN expression. The expression level of IGF-1R has been correlated with tumor metastasis. 
Blocking IGF-1R with anti-IGF-1R antibodies resulted in the inhibition of neuroblastoma cell 
growth and tumor regression in neuroblastoma xenograft mouse models. The anti-IGF-1R 
monoclonal antibody (IMC-A12) is under investigation in phase II trial [54].
2.10. Targeting tropomyosin receptor kinase (TRK)
TRK is now known as the high-affinity receptor for nerve growth factor and as such is cru-
cially involved in the growth, differentiation, and apoptosis of neuronal cells in both the cen-
tral and the peripheral nervous systems. High expression levels of TRK have been correlated 
with poor outcome in neuroblastoma and chemotherapy resistance. Several TRK-blocking 
small compounds, such as CEP-701, have been developed. Blocking TRK using CEP-701 
results in induction of apoptosis and growth inhibition of human neuroblastoma xenografts 
in nude mice. CEP-701 is under investigation in phase I trial for refractory and relapsed neu-
roblastoma. Other tyrosine kinase inhibitors, including inhibitors of the epidermal growth 
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factor receptor, might have activity against neuroblastoma [55]. Imantanib mesylate has also 
been investigated in neuroblastoma because some tumors appear to express c-kit, PDGFR, or 
both; however, activating mutations in these receptors have not been reported [56].
2.11. Targeting Aurora A kinase (AURKA)
AURKA is a serine/threonine kinase, which stabilizes the microtubule at the spindle pole dur-
ing segregation of chromosomes. Based on this, AURKA is essential for G2-M progression, and 
its inhibition results in cell cycle arrest and apoptosis. AURKA is overexpressed in neuroblas-
toma, and amplification of its gene has also been observed in neuroblastoma cells. In phase I 
trials, promising results have also been obtained with AURKA inhibitor MLN8237 [57].
2.12. Targeting PI3K/AKT/mTOR pathway
The PI3K/AKT/mTOR pathway is an intracellular signaling pathway important in regulat-
ing the cell cycle. Therefore, it is directly related to cellular quiescence, proliferation, cancer, 
and longevity. PI3K activation phosphorylates and activates AKT that sequentially activates 
mTOR. In many cancers, this pathway is overactive, thus reducing apoptosis and allowing 
proliferation. Rapamycin (Sirolimus), an antifungal agent with immunosuppressive proper-
ties, was first isolated in 1975 from the soil of the island of Rapa Nui or Easter Island. In 
the 1980s, rapamycin showed a broad anticancer activity. However, clinical development of 
rapamycin as an anticancer agent was hampered by unfavorable pharmacokinetics. Recent 
development of rapamycin analogs with favorable pharmacokinetics such as temsirolimus, 
everolimus, and ridaforolimus opened up the present era of mTOR inhibitors as anticancer 
agents [58].
2.13. Other strategies
Epigenetic silencing of genes that are crucial for induction of apoptosis, such as caspase-8, 
seems to occur frequently in neuroblastoma. Therefore, demethylating agents such as 
decitabine are currently being investigated. Histone deacetylase inhibitors showed preclini-
cal activity against neuroblastoma. More than three histone deacetylase inhibitors are now in 
clinical trials for patients with refractory solid tumors. Heat shock protein 90 inhibitors are 
also of interest because they alter the function of molecules associated with neuroblastoma 
cell growth and proliferation, including AKT, IGF-1, and TrkB [59].
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